[{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"HQP1351","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"HQP1351","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascentage Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PharmaBlock Sciences","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"HQP1351","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase II","graph3":"PharmaBlock Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaBlock Sciences \/ Ascentage Pharma","highestDevelopmentStatusID":"8","companyTruncated":"PharmaBlock Sciences \/ Ascentage Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for HQP1351

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Ascentage's lead drug, HQP1351, is developed to treat drug-resistant chronic myeloid leukemia. PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two parties will continue to advance and expand CDMO cooperation for current and fu...

                          Brand Name : HQP1351

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 14, 2020

                          Lead Product(s) : HQP1351

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Ascentage Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Guangzhou Healthquest Pharma has submitted a NDA to the Center for Drug Evaluation of China National Medical Products Administration for HQP1351 for the treatment of patients with T315I-mutant chronic phase chronic myeloid leukemia and accelerated phase ...

                          Brand Name : HQP1351

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 18, 2020

                          Lead Product(s) : HQP1351

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : HQP1351 is the first 3rd generation BCR-ABL inhibitor developed in China targeting drug-resistant CML. A pivotal Phase II study is currently under way to test HQP1351. Ascentage plans to file an NDA.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 04, 2020

                          Lead Product(s) : HQP1351

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank